| P2093 | author name string | Sylvain Goutelle | |
| | Michel Tod | |
| | Fannie Clavel-Grabit | |
| | Laurent Bourguignon | |
| | Nathalie Bleyzac | |
| | Johanna Berry | |
| P2860 | cites work | Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects | Q24564755 |
| | Simulation and prediction of in vivo drug metabolism in human populations from in vitro data | Q28286115 |
| | Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects | Q28343864 |
| | Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects | Q29308187 |
| | Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data | Q30818645 |
| | Database analyses for the prediction of in vivo drug-drug interactions from in vitro data | Q30913359 |
| | The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions | Q31007823 |
| | Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects | Q33155841 |
| | Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction | Q33437572 |
| | Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype | Q33608028 |
| | Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism | Q34213621 |
| | Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future | Q34310938 |
| | CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor | Q34583603 |
| | General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs | Q34656231 |
| | Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients | Q35120591 |
| | The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance | Q46715801 |
| | Voriconazole and fluconazole increase the exposure to oral diazepam | Q48577491 |
| | Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. | Q51426110 |
| | Interethnic difference in omeprazole's inhibition of diazepam metabolism* | Q51599922 |
| | Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. | Q51620677 |
| | The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. | Q51773857 |
| | Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. | Q51935059 |
| | Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. | Q52070687 |
| | Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir | Q56829869 |
| | Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments | Q73045816 |
| | Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations | Q79488699 |
| | Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes | Q79750040 |
| | Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites | Q83136252 |
| | Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole | Q84571475 |
| | Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies | Q85036168 |
| | Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19 | Q35803627 |
| | Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes | Q35826075 |
| | Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine | Q35827117 |
| | Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status | Q35827487 |
| | A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology | Q35846700 |
| | Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. | Q36094919 |
| | Drug metabolism and variability among patients in drug response | Q36139862 |
| | Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians | Q36729180 |
| | Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers | Q36729190 |
| | The clinical role of genetic polymorphisms in drug-metabolizing enzymes | Q36840621 |
| | Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite | Q37471054 |
| | Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel | Q37892728 |
| | Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions | Q39730908 |
| | Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism | Q41593466 |
| | Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole | Q42144423 |
| | Association between CYP2C19 genotype and proguanil oxidative polymorphism | Q42284701 |
| | Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects | Q42547981 |
| | Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype | Q42677554 |
| | Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers | Q42910898 |
| | Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. | Q43258734 |
| | A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism | Q43270261 |
| | The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers | Q43454795 |
| | Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. | Q43579883 |
| | Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes | Q43622668 |
| | Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram | Q43675348 |
| | CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects | Q43689056 |
| | Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. | Q43721876 |
| | Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism | Q43792962 |
| | Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. | Q43817651 |
| | The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients | Q43837406 |
| | Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers | Q43947373 |
| | CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole | Q44273424 |
| | Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors | Q44337470 |
| | Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. | Q44585457 |
| | Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics | Q44603273 |
| | Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers | Q44942742 |
| | Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans | Q45000642 |
| | Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations | Q45001414 |
| | General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information | Q45041991 |
| | Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms | Q45073052 |
| | Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes | Q45117146 |
| | Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. | Q45974065 |
| | Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. | Q46031110 |
| | Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. | Q46034425 |
| | Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients | Q46447657 |
| | Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects | Q46463147 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 415-426 | |
| P577 | publication date | 2013-01-15 | |
| P1433 | published in | The AAPS Journal | Q10695361 |
| P1476 | title | In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates | |
| P478 | volume | 15 | |